Spine’s technology pipeline has rarely looked fuller. In the first seven months of 2026, Becker’s has reported on devices ranging from personalized implants to cost-effective iPhone based navigation devices.
What has changed is not the rate of invention but rather the sequence a technology has to survive to reach patients. Gaining FDA clearance was once the milestone that defined a launch; now it is now the least difficult step. The gates that better determine whether a technology succeeds are published clinical evidence and a payment pathway.
Judged that way, these five developments sit at different stages of maturity.
1. Personalized implants: A technology that cleared all three gates
AI-driven planning paired with 3D-printed, patient-specific interbodies is the clearest case of a spine technology completing the sequence.
Two-year data on Carlsmed’s aprevo platform compared 115 adult spinal deformity patients treated with the personalized implant against 997 patients who received stock devices. The complication-related reoperation rate was 4.3% in the personalized cohort and 16.6% in the stock cohort. An earlier study found personalized spacers improved achievement of pelvic incidence and lumbar lordosis targets within 5 degrees of the surgeon’s plan.
What set this technology apart was its ability to cross the evidence and payment gates alongside each other. The company’s cervical implant earned CMS’ New Technology Add-On Payment before its commercial launch in December, following a first cervical case in July 2025. Add-on payment does not make personalization free, but it counters the argument that a custom implant is an unreimbursed cost center.
Gate status: All three have been cleared. One element spine leaders should consider: whether the economics hold as the technology moves from deformity cases into routine one- and two-level fusions.
2. AI in patient selection: No 501(k) clearance required, and payers got there first
AI development in spine is not just documentation. It is the migration of AI from the notetaker, to a decision-maker, on who is eligible for operation.
The pitch for AI is that large language models can provide physicians with decision-making context. D. Kojo Hamilton, MD, professor of neurological surgery at the University of Pittsburgh School of Medicine, has described a shift away from static radiographic targets toward patient-specific digital twins. At Rothman Orthopaedics in Philadelphia, President Alex Vaccaro, MD, PhD, said ambient documentation will feed a patient selection platform drawing on imaging and wearable data.
However, the evidence gate has not been cleared in this case. Spine surgeons Daniel Park, MD, and Kern Singh, MD, of Chicago-based Rush University Medical Center, have argued that LLMs predict text rather than reason clinically, and that their present value is in supporting judgment, not substituting for it.
Meanwhile, payers have deployed the same class of tools against surgeons. William Kemp, MD, a spine surgeon in Richmond, Va., told Becker’s that insurers are using AI to police physical therapy documentation.
Gate status: No 501(k) clearance needed. The evidence is immature, and the payment gate can be used against the technology’s adopters rather than for them.
3. Endoscopic decompression: The evidence arrived before the coverage
Endoscopic spine surgery spent a decade as a niche technique. In 2026, it has the data of a mainstream procedure.
A systematic review published in the March issue of The Spine Journal pooled 29 studies and nearly 2,500 patients to quantify what surgeons had described only anecdotally. The median number of cases to reach the learning curve threshold was 20 for uniportal technique and 37.5 for biportal. Minimally invasive approaches have also been associated with lower opioid consumption, with endoscopic cases showing the lowest average use.
Kai-Uwe Lewandrowski, MD, told Becker’s the larger barrier is implementation rather than the learning curve itself. And coverage remains inconsistent enough that at least one surgeon has stopped contracting with commercial payers in part over endoscopic denials.
Gate status: The 501(k) clearance and evidence gates have been cleared, but payment is contested.
4. Handheld navigation: The argument that shrank the robot
One development runs counter to the usual direction of surgical technology: The capital requirement is falling, not rising.
Paul McAfee, MD, director of the Baltimore-based Scoliosis and Spine Center of Maryland, plans cases on an iPhone in a sterile mount costing roughly $1,200, using the same consumer-augmented reality sensors found in any recent handset.
That reframes a purchase decision ASCs have wrestled with for years. Travis Doering, MD, an orthopedic surgeon in Austin, Texas, said at Becker’s Future of Spine Conference in June that the literature supporting widespread robot use still is not there. A robot that cannot generate the case volume to justify its price is a fixed cost; a $1,200 mount is not.
Gate status: The evidence gate is the open question; the payment gate largely disappears when the capital requirement does.
5. Restorative neuromodulation: Coverage as the product
For devices targeting patients who are not surgical candidates, the coverage decision is itself the launch.
Highmark established coverage for Mainstay Medical’s ReActiv8 restorative neurostimulation therapy effective July 27, naming it the only therapy considered medically necessary under the policy when criteria are met. The device treats chronic low back pain associated with multifidus muscle dysfunction in patients who have failed conservative care and are not fusion candidates — a population spine practices see constantly and for which they rarely can bill.
Gate status: The 501(k) clearance and evidence gates were cleared years ago. The 2026 development is navigating access to the payment gate.
What this means for spine programs
Becker’s has covered many devices receiving 501(k) clearance in 2026. While building the tech appears to be easier, getting paid for it is harder. CMS’ 2027 proposed rule would add 618 codes to the ASC-covered list while cutting payment for several high-volume procedures, and an OrthoCarolina analysis found prior authorization delayed elective spine surgery an average of 15.7 days without producing savings. There are more cases coming through the doors, but they cost less than they did before.
Programs that can document outcomes are the ones positioned to argue for new technology. Those that cannot capture Oswestry Disability Index or PROMIS scores before and after surgery lack a baseline to show a payer.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.